Cytiva_Jan2022_mRNAVaccinesANewEra - 10

Increasing mRNA Capabilities And Capacity for Growing Market Needs
Increasing mRNA
Capabilities And Capacity for
Growing Market Needs
By Sebastian Almeida, Director, CMC, Akron Biotech; Lloyd Jeffs, Director, Clinical
Manufacturing Solutions, Precision NanoSystems; John Harmer, Head of Marketing,
Aseptic Filling, and Katarina Stenklo, Enterprise Solutions Activation Leader, Cytiva
After more than a year of enduring myriad
economic and social disruptions and a
devastating loss of life from the COVID-19
crisis, the pharmaceutical industry was able
to deliver its first tools in the fight against the
pandemic. The catalyst for this milestone was
the rapid development of innovative vaccines.
The emergency use authorization (EUA) of
the Moderna and Pfizer-BioNTech vaccines,
which offer 94% efficacy for fully vaccinated
adults, was impressive.1 Both vaccines rely
10 | GENengnews.com
on messenger RNA (mRNA), which delivers
instructions to human cells on how to fight
COVID-19 through a biological Trojan horse.
The ability to " program " mRNA with genetic
code to treat/prevent disease has been
known for decades with clinical testing of
some mRNA vaccines underway even prior
to the rise of COVID2; however, challenges
associated with transitioning mRNA into a
drug product and an industry averse to change
have historically hindered its potential.
https://www.genengnews.com https://www.genengnews.com

Cytiva_Jan2022_mRNAVaccinesANewEra

Table of Contents for the Digital Edition of Cytiva_Jan2022_mRNAVaccinesANewEra

Contents
Cytiva_Jan2022_mRNAVaccinesANewEra - Cover1
Cytiva_Jan2022_mRNAVaccinesANewEra - Cover2
Cytiva_Jan2022_mRNAVaccinesANewEra - Contents
Cytiva_Jan2022_mRNAVaccinesANewEra - 4
Cytiva_Jan2022_mRNAVaccinesANewEra - 5
Cytiva_Jan2022_mRNAVaccinesANewEra - 6
Cytiva_Jan2022_mRNAVaccinesANewEra - 7
Cytiva_Jan2022_mRNAVaccinesANewEra - 8
Cytiva_Jan2022_mRNAVaccinesANewEra - 9
Cytiva_Jan2022_mRNAVaccinesANewEra - 10
Cytiva_Jan2022_mRNAVaccinesANewEra - 11
Cytiva_Jan2022_mRNAVaccinesANewEra - 12
Cytiva_Jan2022_mRNAVaccinesANewEra - 13
Cytiva_Jan2022_mRNAVaccinesANewEra - 14
Cytiva_Jan2022_mRNAVaccinesANewEra - 15
Cytiva_Jan2022_mRNAVaccinesANewEra - 16
Cytiva_Jan2022_mRNAVaccinesANewEra - 17
Cytiva_Jan2022_mRNAVaccinesANewEra - 18
Cytiva_Jan2022_mRNAVaccinesANewEra - 19
Cytiva_Jan2022_mRNAVaccinesANewEra - 20
Cytiva_Jan2022_mRNAVaccinesANewEra - 21
Cytiva_Jan2022_mRNAVaccinesANewEra - 22
Cytiva_Jan2022_mRNAVaccinesANewEra - 23
Cytiva_Jan2022_mRNAVaccinesANewEra - 24
Cytiva_Jan2022_mRNAVaccinesANewEra - 25
Cytiva_Jan2022_mRNAVaccinesANewEra - 26
Cytiva_Jan2022_mRNAVaccinesANewEra - 27
Cytiva_Jan2022_mRNAVaccinesANewEra - Cover3
Cytiva_Jan2022_mRNAVaccinesANewEra - Cover4
https://www.nxtbookmedia.com